search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
NEWSWIRE


distributors to get PPE and other critical supplies into the country and to their re- spective customers. FEMA is doing this by covering the cost


to fly supplies into the .S. from overseas factories, cutting the amount of time it taes to ship supplies from months to days. ach flight contains critical  (gloves, gowns, goggles, and mass) in varying quantities. As part of the current agreement with distributors,  percent of the supplies on each plane are targeted by the distributors to customers in areas of greatest need. hese areas are determined by S and FEMA based on CDC data. he remainder is being infused into the broader .S. supply chain. rioritization is given to hospitals, healthcare facilities, and nursing homes around the country. n some cases, the federal government


may purchase some of the supplies to provide to states with any identified and unmet needs. To address the anticipated ventilator shortage across the nation, the tas force has also implemented a strategy to lever- age the strengths of the commercial in- dustry including numerous vendors, such as eneral lectric, hillips, edtronic, amilton, oll, Resed, illrom and Vyair, to produce , ventilators over the next two months with the potential to add , by end of une. his represents a significant increase in velocity as the normal annual maret is 3, per year. Expansion xpansion of the industry is also taing


place. anufacturers are enhancing pro- duction capacity with additional machin- ery, and in some cases re-tooling assembly lines to produce new products needed. As an example of this wor, the FA is providing information for manufacturers on adding production lines or alternative sites, lie automobile manufacturers, for making more ventilators during the CO- VID-19 public health emergency. n addition, the tas force is woring


through over 3 leads to match American businesses that have excess raw materials, worforce or factory production capacity combined with an overwhelming desire to provide their support to the national response effort. as force members are actively woring


to facilitate the creation of private sector partnerships to pair companies that have volunteered excess factory production capacity, the talents of their worforce and access to their raw material supply chains with critical supply manufacturers that have the expertise in producing , ventilator and other needed equipment.


he creation of these partnerships to align capacity with know-how will unleash the potential engine of our national private sec- tor and help overcome the supply shortfalls. Allocation Allocation of critical resources based on data-informed decisions to get the right quantities of supplies to the right place, at the right time is imperative.


Because FEMA owns very little medical supplies and the commercial marketplace supports the healthcare and first responder communities today, there is a need to provide commercial supply chain data to FEMA. o more effectively adudicate resources throughout the nation and private indus- try, a ational Resource rioritization Cell was established to unify government and private industry prioritization recommen- dations which will inform federal, state and private sector operations. he Supply Chain as Force is woring


with the maor commercial distributors to facilitate the rapid distribution of critical resources in short supply to locations where they are needed most.


This partnership enables FEMA and its federal partners to tae a whole-of-America approach to combatting COV-. FA, in coordination with other federal agencies, is providing distributors with up-to-date information on the locations across the country hardest hit by COVID-19 or in most need of resources now and in the future. he distributors have agreed to focus portions of their distributions on these areas in order to alleviate the suffering of the American people. FA says that by woring together,


they will be able to efficiently distribute these vital resources to hospitals, nurs- ing homes, long-term care facilities, pre- hospital medical services, state and local governments, and other facilities critical to caring for the American people during this pandemic.


NIH begins study to quantify undetected cases of COVID-19 A new study has begun recruiting at the ational nstitutes of ealth () in Bethesda, , to determine how many adults in the nited States without a confirmed history of infection with SARS- CoV-, the virus that causes coronavirus disease  (COV-), have antibodies to the virus. he presence of antibodies in the blood indicates a prior infection. n this serosurvey,” researchers will collect and analyze blood samples from as many as , volunteers to provide critical data for epidemiological models. The results will help illuminate the extent


8 May 2020 • HEALTHCARE PURCHASING NEWS • hpnonline.com


to which the novel coronavirus has spread undetected in the nited States and pro- vide insights into which communities and populations are most affected. The study will be conducted by research-


ers at the ational nstitute of Allergy and nfectious iseases (A) and the a- tional nstitute of Biomedical maging and Bioengineering (BB), with additional support from the ational Center for Ad- vancing ranslational Sciences (CAS) and the ational Cancer nstitute (C), all parts of .


“This study will give us a clearer picture


of the true magnitude of the COV- pandemic in the nited States by telling us how many people in different communities have been infected without nowing it, be- cause they had a very mild, undocumented illness or did not access testing while they were sic,” said Anthony S. Fauci, .., A director. hese crucial data will help us measure the impact of our public health efforts now and guide our COV- response moving forward.”


Investigators will test participants’ blood samples for the presence of SARS-CoV- antibodies, proteins the immune system produces to fight a specific infectious agent. A positive test result indicates previous infection. o date, reporting of .S. cases of COVID-19 has mostly relied on molecular tests that determine the presence of the virus in a person’s airways using a non- invasive cotton swab. While these cotton swab-based tests rapidly and effectively identify active infection, they do not de- termine whether a person was previously infected with SARS-CoV- and recovered. nvestigators will analyze blood samples


for two types of antibodies, anti-SARS- CoV- S protein g and g, using an LSA (enzyme-lined immunosorbent assay) developed by researchers at A and BB. n blood samples found to contain antibodies against SARS-CoV-, researchers may perform additional tests to evaluate the volunteers’ immune responses to the virus. These data may provide insight as to why these cases were less severe than those that lead to hospitalization. ealthy volunteers over the age of  from anywhere in the nited States can partici- pate and will be asked to consent to enroll- ment over the telephone. Individuals with a confirmed history of COV- or current symptoms consistent with COVID-19 are not eligible to participate. After enrollment, study participants will


attend a virtual clinic visit, complete a health assessment questionnaire and provide basic demographic informationincluding race, ethnicity, sex, age and occupationbefore submitting samples in one of two ways. HPN


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58